A survey study of sarcopenia screening, nutritional assessment and frailty assessment of elderly inpatients with prostate diseases

doi:10.3877/cma.j.issn.2095-8757.2025.02.003

Abstract

Abstract:

Objective

To screen for sarcopenia, assess nutritional status, and evaluate frailty in elderly hospitalized patients with prostate diseases, and to analyze the risk factors affecting the occurrence of prostate cancer among them.

Methods

Elderly patients with prostatic hyperplasia and prostate cancer initially diagnosed and admitted to the Second Hospital of Tianjin Medical University between January and June 2024 were selected. The patient's height, weight, waist circumference, calf circumference, and grip strength were measured. Sarcopenia was screened using the SARC-CalF scale, malnutrition was diagnosed using the GLIM criteria, and frailty was diagnosed using the Fried phenotype criteria. T test and χ² test were used to compare the clinical data of patients with benign prostatic hyperplasia and those with prostate cancer. Multivariate Logistic regression analysis was performed to identify risk factors influencing the occurrence of prostate cancer.

Results

A total of 656 patients were enrolled. Among them, 24 cases (3.66%) were at risk for sarcopenia, 80 cases (12.20%) had malnutrition, and 256 cases (39.02%) were frail. There were 424 cases of patients with benign prostatic hyperplasia (benign prostatic hyperplasia group) and 232 cases of patients with prostate cancer (prostate cancer group). The incidence of low calf circumference and low grip strength in the prostate cancer group was significantly higher than that in the benign prostatic hyperplasia group (14.29% vs 1.92%, χ²=4.747, P < 0.05; 51.72% vs 28.30%, χ²=4.432, P < 0.05). The incidence of sarcopenia and frailty was significantly higher in the prostate cancer group than in the benign prostatic hyperplasia group (10.34% vs 0, χ²=5.691, P < 0.05, 62.07% vs 26.42%, χ²=10.013, P < 0.05). Logistic regression analysis revealed that frailty was a risk factor for the occurrence of prostate cancer (OR=11.63, 95%CI: 1.05-125.00, P < 0.05).

Conclusion

The incidence of frailty among prostate cancer patients is relatively high, and frailty is one of the risk factors for the occurrence of prostate cancer.

Key words: Prostatic hyperplasia, Prostate cancer, Frailty, Sarcopenia, Malnutrition, Screening, Evaluation

Jingran Cao, Yong Wang, Baoshuai Zhang, Yi Zhou, Yong Xu. A survey study of sarcopenia screening, nutritional assessment and frailty assessment of elderly inpatients with prostate diseases[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2025, 12(02): 14-18.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2025.02.003

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2025/V12/I02/14

Figures/Tables 2

References 32

[1]	李星，曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究，2021,48(1):98-102.
[2]	中国抗癌协会泌尿男生殖系肿瘤专业委员会，中国临床肿瘤学会前列腺癌专家委员会.中国前列腺癌患者基因检测专家共识(2020年版)[J].中国癌症杂志，2020,30(7):551-560.
[3]	中国抗癌协会男性生殖系统肿瘤专业委员会，叶定伟，邹青. 高危前列腺癌围手术期综合治疗专家共识（2023年版）[J].中国癌症杂志，2023,33(12):1204-1214.
[4]	Pandit P, Shirke C, Bhatia N, et al. An overview of recent findings that shed light on the connection between fat and cancer[J]. Endocr Metab Immune Disord Drug Targets, 2024, 24(2):178-193.
[5]	Zhao Z, Wu D, Gao S, et al. The association between dairy products consumption and prostate cancer risk: A systematic review and meta-analysis[J]. Br J Nutr, 2023, 129(10):1714-1731.
[6]	Orlich MJ, Mashchak AD, Jaceldo-Siegl K, et al. Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study-2[J]. Am J Clin Nutr, 2022, 116(2):314-324.
[7]	Hartrampf PE, Mihatsch PW, Seitz AK, et al. Elevated body mass index is associated with improved overall survival in castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen-directed radioligand therapy[J]. J Nucl Med, 2023, 64(8):1272-1278.
[8]	Murphy S, Rahmy S, Gan D, et al. Overcome prostate cancer resistance to immune checkpoint therapy with ketogenic diet-induced epigenetic reprogramming[J]. bioRxiv, 2023, DOI:10.1101/2023.08.07.552383.
[9]	黄健.中国泌尿外科和男科疾病诊断治疗指南[M].北京：科学出版社，2022：130-140.
[10]	霍军生.营养筛查诊断与评估[M].北京：人民卫生出版社，2020：20-26.
[11]	杨月欣.中国营养科学全书[M]. 北京：人民卫生出版社，2019：1180-1182.
[12]	曹晓芳，王倩，李淑莹，等.握力对老年住院患者老年综合征的影响[J].中华老年医学杂志，2021,40(10):1286-1290.
[13]	Kondrup J, Allison SP, Elia M, et al. ESPEN guidelines for nutrition screening 2002[J]. Clin Nutr, 2003, 22(4):415-421.
[14]	Cederholm T, Jensen G L, Correia M, et al. GLIM criteria for the diagnosis of malnutrition-A consensus report from the global clinical nutrition community[J]. Clin Nutr, 2019, 38(1):1-9.
[15]	Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People[J]. Age Ageing, 2010, 39(4):412-423.
[16]	Dent E, Morley JE, Cruz-Jentoft AJ, et al. Physical frailty: ICFSR international clinical practice guidelines for identification and management[J]. J Nutr Health Aging, 2019, 23(9):771-787.
[17]	Nguyenhuy M, Chang J, Xu R, et al. The fried frailty phenotype in patients undergoing cardiac surgery: A systematic review and meta-analysis[J]. Heart Surg Forum, 2022, 25(5):E652-E659.
[18]	Loh NY, Wang W, Noordam R, et al. Obesity, fat distribution and risk of cancer in women and men: A mendelian randomisation study[J]. Nutrients, 2022, 14(24):5259.
[19]	Wilson RL, Taaffe DR, Newton RU, et al. Obesity and prostate cancer: A narrative review[J]. Crit Rev Oncol Hematol, 2022, 169:103543.
[20]	Belladelli F, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk[J]. Curr Opin Urol, 2022, 32(6):594-597.
[21]	Saha A, Kolonin MG, DiGiovanni J. Obesity and prostate cancer-microenvironmental roles of adipose tissue[J]. Nat Rev Urol, 2023, 20(10):579-596.
[22]	Olivas A, Price RS. Obesity, inflammation, and advanced prostate cancer[J]. Nutr Cancer, 2021, 73(11-12):2232-2248.
[23]	曹婧然，刘炜，陈康寅，等.营养相关血液标志物及营养风险对衰弱的诊断价值研究[J].中国临床实用医学，2023,14(5):17-21.
[24]	Kiriukova M, de la Iglesia GD, Panic N, et al. Pancreatic cancer malnutrition and pancreatic exocrine insufficiency in the course of chemotherapy in unresectable pancreatic cancer[J]. Front Med(Lausanne), 2020, 7:495.
[25]	Seyfried TN. The effects of diet on prostate cancer outcomes[J]. Nat Rev Urol, 2022, 19(7):389-390.
[26]	Kovac MB, Pavlin T, Cavka L, et al. The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis[J]. J Geriatr Oncol, 2023, 14(7):101594.
[27]	Mafla-Espana MA, Torregrosa MD, Cauli O. Analysis of frailty syndrome in men with metastatic prostate cancer: A scoping review[J]. J Pers Med, 2023, 13(2):338.
[28]	de Pablos-Rodriguez P, Del PT, Infante-Ventura D, et al. Prognostic impact of sarcopenia in patients with advanced prostate carcinoma: A Systematic Review[J]. J Clin Med, 2022, 12(1):57.
[29]	Cho MR, Lee S, Song SK. A review of sarcopenia pathophysiology, diagnosis, treatment and future direction[J]. J Korean Med Sci, 2022, 37(18):e146.
[30]	Nishikawa H, Fukunishi S, Asai A, et al. Pathophysiology and mechanisms of primary sarcopenia (Review)[J]. Int J Mol Med, 2021, 48(2):156.
[31]	Bargiota A, Oeconomou A, Zachos I, et al. Adverse effects of androgen deprivation therapy in patients with prostate cancer: Focus on muscle and bone health[J]. J BUON, 2020, 25(3):1286-1294.
[32]	Cavka L, Pohar PM, Zakotnik B, et al. Nutritional status and health-related quality of life in men with advanced castrate-resistant prostate cancer[J]. Nutr Cancer, 2022, 74(2):472-481.

组别	例数	年龄（岁）	BMI（kg/m²）	低小腿围	低握力	营养不良	肌少症	衰弱
前列腺增生组	424	68.30±6.32	24.44±2.96	8（1.92）	120（28.30）	32（7.55）	0（0）	112（26.42）
前列腺癌组	232	65.69±9.06	24.08±3.07	32（14.29）	120（51.72）	48（20.69）	24（10.34）	144（62.07）
检验值		t=-0.227	t=0.514	χ²=4.747	χ²=4.432	χ²=3.024	χ²=5.691	χ²=10.013
P值		>0.05	>0.05	<0.05	<0.05	>0.05	<0.05	<0.01

组别	例数	年龄（岁）	BMI（kg/m²）	低小腿围	低握力	营养不良	肌少症	衰弱
前列腺增生组	424	68.30±6.32	24.44±2.96	8（1.92）	120（28.30）	32（7.55）	0（0）	112（26.42）
前列腺癌组	232	65.69±9.06	24.08±3.07	32（14.29）	120（51.72）	48（20.69）	24（10.34）	144（62.07）
检验值		t=-0.227	t=0.514	χ²=4.747	χ²=4.432	χ²=3.024	χ²=5.691	χ²=10.013
P值		>0.05	>0.05	<0.05	<0.05	>0.05	<0.05	<0.01

自变量	β值	SE	Wald χ²	P值	OR（95%CI）
年龄	-0.011	0.043	0.112	0.732	0.978（0.914-1.069）
低握力	0.873	1.314	0.444	0.507	2.396（0.182-31.641）
低小腿围	-2.049	1.263	2.637	0.100	0.133（0.014-1.536）
NRS2002	0.453	0.268	2.716	0.100	1.566（0.922-2.682）
SARC-CalF	-0.042	0.112	0.154	0.703	0.964（0.773-1.193）
Fried	0.881	0.417	4.251	0.043	11.632（1.049-125.000）

自变量	β值	SE	Wald χ²	P值	OR（95%CI）
年龄	-0.011	0.043	0.112	0.732	0.978（0.914-1.069）
低握力	0.873	1.314	0.444	0.507	2.396（0.182-31.641）
低小腿围	-2.049	1.263	2.637	0.100	0.133（0.014-1.536）
NRS2002	0.453	0.268	2.716	0.100	1.566（0.922-2.682）
SARC-CalF	-0.042	0.112	0.154	0.703	0.964（0.773-1.193）
Fried	0.881	0.417	4.251	0.043	11.632（1.049-125.000）

Please choose a citation manager

Content to export